Dr. Jasmine Luzum’s (formerly Talameh) research focuses on the improvement of pharmacologic outcomes and reduction of racial disparities in patients with cardiovascular disease, especially heart failure. She uses a variety of clinical & translational research approaches, with an emphasis on pharmacogenomics. Her research has been funded by the most prestigious sponsors, published in top journals, and presented at major conferences.
Dr. Luzum joined the University of Michigan in July 2016. She received her PharmD summa cum laude from the University of Pittsburgh in 2008 and her PhD in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill Eshelman School of Pharmacy in 2013. She completed a Post-Doctoral Fellowship at the Ohio State University College of Medicine and Center for Pharmacogenomics in 2016. She became a Board-Certified Pharmacotherapy Specialist by the Board of Pharmacy Specialties and an Applied Pharmacologist by the American Board of Clinical Pharmacology in 2015.
U-M Pharmacy Professor Jasmine Luzum Named Rising Star
Dr. Jasmine Luzum was named a Rising Star by her alma mater, the University of Pittsburgh School of Pharmacy.
- 2021 Top Trainee Poster Award (for my post-doc Alessandra Campos-Staffico), Pharmacogenomics Global Research Network
- 2021 Scholar of the Health Disparity Research Institute, National Institute on Minority Health and Health Disparities
- 2021 Fellow of the Heart Failure Society of America (FHFSA), Heart Failure Society of America
- 2021 Fellow of the American Heart Association, American Heart Association
- 2020 Honorary Poster Award for my PDI student Derek Linskey, Pharmacogenomics Research Network
- 2019 Rising Star Award, University of Pittsburgh College of Pharmacy
- 2019 M. Kelli Jordan Travel Award (awarded to my post-doc Tyler Shugg), ACCP
- 2018 Pharmacist Travel Grant Award, Heart Failure Society of America
- 2018 NIH Loan Repayment Program Ambassador Spotlight , NIH Loan Repayment Program
- 2018 Finalist for the Jay N. Cohn New Investigator Award , Heart Failure Society of America
Campos-Staffico, A. M., Cordwin, D., Ding, Y., Lester, C. A., Brook, R. D., Luzum, J. A., & Dorsch, M. P. (2021). Fewer patients receive recommendations for pharmacotherapy in primary prevention using the 2018 atherosclerotic cardiovascular disease risk estimator. Preventive Medicine, 148, 106555. https://doi.org/10.1016/j.ypmed.2021.106555
Gui, H., She, R., Luzum, J., Li, J., Bryson, T. D., Pinto, Y., Sabbah, H. N., Williams, L. K., & Lanfear, D. E. (2021). Plasma proteomic profile predicts survival in heart failure with reduced ejection fraction. Circulation: Genomic and Precision Medicine, 14(3). https://doi.org/10.1161/circgen.120.003140
Lanfear, D. E., & Luzum, J. A. (2021). BNP and precision medicine. JACC: Basic to Translational Science, 6(6), 505–506. https://doi.org/10.1016/j.jacbts.2021.05.007
Luzum, J. A., Petry, N., Taylor, A. K., Van Driest, S. L., Dunnenberger, H. M., & Cavallari, L. H. (2021). Moving pharmacogenetics into practice: It’s all about the evidence! Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.2327
Patel, J. N., Jiang, C., Owzar, K., Mulkey, F., Luzum, J. A., Mamon, H. J., Haller, D. G., Dragovich, T., Alberts, S. R., Bjarnason, G., Willet, C. G., Niedzwiecki, D., Enzinger, P., Ratain, M. J., Fuchs, C., & McLeod, H. L. (2021).Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance). Pharmacogenetics and Genomics, Publish Ahead of Print. https://doi.org/10.1097/fpc.0000000000000442